Suppr超能文献

利用5'RACE鉴定间变性淋巴瘤激酶变异易位

Identification of anaplastic lymphoma kinase variant translocations using 5'RACE.

作者信息

Hernández Luis, Campo Elias

机构信息

Department of Pathology, Hospital Clinic, University of Barcelona, Spain.

出版信息

Methods Mol Med. 2005;115:295-314. doi: 10.1385/1-59259-936-2:295.

Abstract

Anaplastic lymphoma kinase (ALK) is abnormally expressed in anaplastic large cell lymphoma (ALCL) and its expression associated with chromosomal translocations involving the ALK gene at 2p23. These translocations lead to the synthesis of novel chimeric proteins that retain the C-terminal portion of ALK, where the tyrosine kinase domain is located. In most of these tumors, the t(2;5)(p23;q35) translocation causes fusion of the ALK gene to the 5' region of the nucleophosmin (NPM) gene, but other different ALK partners have been identified, including nonmuscle tropomyosin (TPM3), TRK-fused gene (TFG), 5' aminoimidazole-4-carboxamide ribonucleotide formyltranferase/IMP cyclohydrolase (ATIC), clathrin heavy chain gene (CLTC), and moesin (MSN). The characterization of these ALK partners has been performed using different molecular methods, including the 5' Rapid Amplification of complementary deoxyribonucleic acid (cDNA) Ends (5'RACE) polymerase chain reaction (PCR)-based technique. This approach allows the potential amplification and identification of either 5' or 3' mRNA ends from an internal known sequence. In ALK translocations, identification of the 5' gene involved has been performed using primers designed within the known 3' catalytic domain of the ALK. Initial reaction consists in a first-strand cDNA synthesis primed using a gene-specific antisense primer (ALK1), performing the cDNA conversion of specific messenger ribonucleic acids, and maximizing the potential for complete extension to the 5'-end of the message. After cDNA synthesis, the first-strand product is purified from unincorporated dNTPs and ALK1. Terminal deoxynucleotidyl transferase is used to add homopolymeric tails to the 3' ends of the cDNA. Tailed cDNA is then amplified by PCR using a nested gene-specific primer (ALK2), which anneals 3' to ALK1, and a complementary homopolymer containing an anchor primer (i.e., AAP), which permits amplification from the homopolymeric tail. This allows amplification of unknown sequences between the ALK2 and the 5' end of the mRNA. Further, nested PCRs usually are required to confer an adequate level of specificity to the process to permit the characterization of RACE products. The reamplification is achieved by using a nested gene-specific primer (ALK3), which anneals 3' to ALK2, and a universal amplification primer, which anneals to the 5' sequence previously introduced by the AAP primer.

摘要

间变性淋巴瘤激酶(ALK)在间变性大细胞淋巴瘤(ALCL)中异常表达,其表达与涉及2p23处ALK基因的染色体易位有关。这些易位导致合成新型嵌合蛋白,这些蛋白保留了ALK的C末端部分,酪氨酸激酶结构域就位于该区域。在大多数这些肿瘤中,t(2;5)(p23;q35)易位导致ALK基因与核磷蛋白(NPM)基因的5'区域融合,但已鉴定出其他不同的ALK伙伴,包括非肌肉原肌球蛋白(TPM3)、TRK融合基因(TFG)、5'-氨基咪唑-4-甲酰胺核糖核苷酸甲酰转移酶/IMP环水解酶(ATIC)、网格蛋白重链基因(CLTC)和埃兹蛋白(MSN)。已使用不同的分子方法对这些ALK伙伴进行了表征,包括基于5'互补脱氧核糖核酸(cDNA)末端快速扩增(5'RACE)聚合酶链反应(PCR)的技术。这种方法允许从内部已知序列潜在地扩增和鉴定5'或3'mRNA末端。在ALK易位中,使用在ALK已知的3'催化结构域内设计的引物来鉴定所涉及的5'基因。初始反应包括使用基因特异性反义引物(ALK1)引发的第一链cDNA合成,进行特定信使核糖核酸的cDNA转化,并最大限度地提高向信使的5'末端完全延伸的可能性。cDNA合成后,从未掺入的脱氧核苷酸三磷酸和ALK1中纯化第一链产物。末端脱氧核苷酸转移酶用于向cDNA的3'末端添加同聚物尾巴。然后使用巢式基因特异性引物(ALK2)通过PCR扩增带尾的cDNA,ALK2在ALK1的3'端退火,以及包含锚定引物(即AAP)的互补同聚物,该引物允许从同聚物尾巴进行扩增。这允许扩增ALK2和mRNA的5'末端之间的未知序列。此外,通常需要进行巢式PCR以赋予该过程足够的特异性水平,以允许表征RACE产物。通过使用在ALK2的3'端退火的巢式基因特异性引物(ALK3)和与先前由AAP引物引入的5'序列退火的通用扩增引物来实现再扩增。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验